Compare Regeneron Pharmaceuticals Inc (REGN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ResMed Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.4× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and ResMed Inc. for 51 Days on average.
| REGN | RMD | |
|---|---|---|
Market Cap | $76.14B | $31.89B |
Volume | 500,239 | 618,314 |
Sector | Health | Health |
52-Week High | $852.03 | $275.96 |
52-Week Low | $557.73 | $182.82 |
Typical Hold Time | 107 Days | 51 Days |
Enterprise Value | $70.85B | $31.24B |
Dividend Yield | 0.51% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% on the day, with a bearish technical signal from moving averages. The company maintains strong fundamentals, including a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant immunology alliance expansion with Sanofi, valued up to $8 billion, which could drive future growth. Cash flow improved in 2025, with net cash flow turning positive at $634.70 million.
The outlook is positive, supported by robust profitability and strategic collaborations, but faces risks from competition in key drug markets and reliance on pipeline success. Analysts are bullish with a consensus price target of $849.84, implying potential upside. Investors should weigh strong financials against execution risks in drug development.
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
